Question special
Lead Moderator

Given the limitations of both LAIV and IIV, how will alternative vaccine delivery routes (e.g. microneedle patch, etc.) change the landscape of influenza vaccine products – specifically with regard to the impact on LAIV – in the pediatric population? Are any new LAIV formulations in the pipeline?